Canada Markets close in 3 hrs 42 mins

InnoCan Pharma Corporation (IP4.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
0.21700.0000 (0.00%)
As of 05:54PM CET. Market open.
Full screen
Previous Close0.2170
Open0.2170
Bid0.1962 x N/A
Ask0.2240 x N/A
Day's Range0.2170 - 0.2170
52 Week Range0.1562 - 0.5570
Volume50
Avg. Volume22,141
Market Cap51.365M
Beta (5Y Monthly)3.84
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Newsfile

    Innocan Pharma Signs a First Consulting Agreement to Commercialize its Pharmaceutical IP in the Veterinary Field

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies, is pleased to announce that it has signed a consulting agreement with Benitz Consulting LLC ("Benitz Consulting") to assist the Company's commercialization of IP in the veterinary field. The principal of Benitz Consulting

  • Newsfile

    Innocan Pharma Reports Q3 2022 Results with 700% Increase in Revenues Compared to Q3 2021

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 29, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan") a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to report its financial results for the three and nine months ended September 30, 2022. "We delivered encouraging results in the third quarter, with revenue growth and ar

  • Newsfile

    Mr. Givi Topchishvili to Join Innocan Pharma's Advisory Committee

    Herzliya, Israel and Calgary, Alberta--(Newsfile Corp. - November 18, 2022) - Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) (the "Company" or "Innocan"), a pharmaceutical technology company focusing on developing innovative drug delivery platform technologies and owner of a proprietary IP portfolio, is pleased to announce the addition of Givi Topchishvili, to Innocan's Advisory Committee, as a business strategy adviser, focused on commercializing of healthcare innovations. Giv